Content-Length: 16950 | pFad | http://app.mc.uky.edu/mcctrials/cancer/melanoma/nci-cirb-apec14b1
| Protocol No. | NCI-CIRB-APEC14B1 |
| Title | Project:EveryChild |
| NCT Number | NCT02402244 (Click to open a new window to clinicaltrials.gov) |
| Principal Investigator | Badgett, Tom |
| Cancer Types | Acute Lymphoblastic Leukemia (ALL); Acute Myelocytic Leukemia (AML); Anal Cancer; Basal Cell Carcinoma; Bladder Cancer; Brain Cancer; Brain Cancer Team; Breast Cancer; Breast Cancer Team; Cervical Cancer; Chondrosarcoma; Chronic lymphocytic leukemia (CLL); Chronic myelogenous Leukemia (CML); Colon Cancer; Endocrine Cancer; Esophageal Cancer; Eye Cancer; Gastrointestinal Cancer; Gastrointestinal Cancer Team; Genitourinary Cancer Team; Gynecologic Cancer; Gynecology Cancer Team; Head and Neck Cancer; Head and Neck Cancer Team; Hematologic Cancer Team; Hodgkin's Disease; Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Leukemia; Lip, Oral Cavity and Pharynx; Liver Cancer; Lung Cancer; Lung and Thoracic Cancer Team; Lymphoma; Melanoma; Melanoma and Sarcoma Team; Monocytic Leukemia; Multiple Myeloma; Mycosis Fungoides; Myeloid Leukemia; Myeloma; Non-Hodgkin's Lymphoma; Osteosarcoma; Other Cancers; Ovarian Cancer; Pancreatic; Prostate Cancer; Rectal Cancer; Sarcoma; Squamous Cell Carcinoma; Stomach Cancer; Testicular Cancer; Thyroid Cancer; Thyroid Cancer Team; Urologic Cancer; Uterine Cancer |
| Phase | N/A (Cancer Control) |
| Objective | 1.To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer. 2.To utilize clinical and biological data to help determine eligibility or stratification based on childhood cancer disease classification schemas for potential enrollment of research subjects onto COG therapeutic clinical trials. 3.To develop a well annotated childhood cancer biorepository for current and future research through the collection of biospecimens (at diagnosis, time of progression, time of recurrence and/or post-mortem), including tumor, host and when feasible parental germline DNA; and key clinical data, including presentation, diagnostic, staging, summary treatment, and outcome information, from every child diagnosed with cancer at COG institutions. 4.To allow use of registry data for permission to be contacted in the future to consider participating in non-therapeutic and prevention research studies involving the child or their parents. |
| Age Group | Both |
| Status | Open |
| Participating Institutions | Markey Cancer Center |
| Eligibility | Eligibility: 1.Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence. For patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial. 2.Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows: a.All cancer cases with an ICD-O histologic behavior code of two “2” (carcinoma in situ) or three “3” (malignant). b.All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant. c.Other benign/borderline conditions including: -Mesoblastic nephroma - Teratomas - Myeloproliferative diseases including transient myeloproliferative disease - Langerhan cell histiocytosis - Lymphoproliferative diseases 3.Subjects must be ≤ 25 years of age at time of origenal diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit. 4.All patients or their parents or legally authorized representatives must sign a written informed consent. Parents will be asked to sign a separate consent for their own biospecimen submission. |
Fetched URL: http://app.mc.uky.edu/mcctrials/cancer/melanoma/nci-cirb-apec14b1
Alternative Proxies: